Then, Now, and Tomorrow: Evolving the Management of Diabetic -

Overview
NoneSponsored by an educational grant from Regeneron Pharmaceuticals, Inc., and Carl Zeiss Meditec, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Discuss the increasing prevalence of diabetes and diabetic retinopathy.
- Identify which patients need to be screened earlier based on their disease state.
- Summarize how imaging devices may be able to provide earlier diagnosis of disease or disease progression.
- Explain to patients the need for early and timely referral to retina specialists.
- Understand the evolving treatment paradigm of diabetic eye disease.
Accreditation
Evolve is an approved COPE Administrator This course is COPE approved for 1.25 hours of CE Credit for Optometrists: COPE Course ID 62184-PS.COPE Activity ID 118198.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests: John D. Pitcher III, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan plc., Genentech, Novartis and Regeneron Pharmaceuticals. Speakers Bureau: Genentech and Regeneron Pharmaceuticals, Inc. Grant Research Support: Alcon. Editorial Support Disclosures Erin K. Fletcher, MIT, director of compliance and education, Evolve and Susan Gallagher-Pecha, director of client services and project management, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Regeneron Pharmaceuticals, Inc. or Carl Zeiss Meditec Inc. OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 11/19/2019

Overview

Learning Objectives

Accreditation

Faculty and Disclosures

Disclaimer

System Requirements

Publication Dates

Recommended

Title